ESR1 and breast carcinoma: In breast cancer, patients with human epidermal growth factor receptor 2 (HER2)-positive, hormone receptor-negative subtypes and those with triple-negative subtypes (negative for estrogen receptor (ER), progesterone receptor (PR), and normal HER2 expression) exhibit a higher incidence of BMs [12].